# Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.

> PubMed lists PMID 20168286 in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) \[and\] the International Association of Radiopharmacology (IAR), \[and\] Section of the Society of... as Clinical Trial, Journal Article, with publication-date metadata of 2010-02 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20168286-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20168286-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-20168286-lanreotide-v1.json
- Content SHA-256: `3aab52d668f9ec05bda8924d548f1e1778da7a43056768d4b95b339fec6c7880`

## Claims and source pins

### Headline

Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. ([`pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869`](#source-pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869))

### Summary

PubMed lists PMID 20168286 in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) \[and\] the International Association of Radiopharmacology (IAR), \[and\] Section of the Society of... as Clinical Trial, Journal Article, with publication-date metadata of 2010-02 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869`](#source-pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869))

### Paragraph 1

PubMed lists PMID 20168286 in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) \[and\] the International Association of Radiopharmacology (IAR), \[and\] Section of the Society of... as Clinical Trial, Journal Article, with publication-date metadata of 2010-02 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869`](#source-pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869`](#source-pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869))

## Sources

<a id="source-pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869"></a>
- **Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. · retained source version 1:2016-11-25:current:d1ab9efa1869c48145852bbef1f2dde7fa559213e4a6dcbd278c26e3c2197c94** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20168286/) (`pubmed-observation-pmid-20168286-2016-11-25-d1ab9efa1869`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-20168286-lanreotide-v1.json SHA-256: 3aab52d668f9ec05bda8924d548f1e1778da7a43056768d4b95b339fec6c7880.